Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …

Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …

The development of precision medicine approaches for diffuse large B cell lymphoma
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …

PURPOSE Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-
cell lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Background Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically
heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B …

Abstract Disease Overview Diffuse large B‐cell lymphoma (DLBCL) is the most common
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …

Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

Purpose High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
(HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to …

A revision of the nearly 8-year-old World Health Organization classification of the lymphoid
neoplasms and the accompanying monograph is being published. It reflects a consensus …